🏛️ Verified NIH Record • Updated 2026-06-25

The Effects of Dupilumab on Allergic Contact Dermatitis (NCT03935971)

🔵 Active, Not Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Brigham and Women's Hospital

🩺 Plain-English Summary (8th-Grade Level)

The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.

Who can join: Review the eligibility criteria below.

Location: Brigham and Women's Hospital, Department of Dermatology — Boston, Massachusetts

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

  • Brigham and Women's Hospital, Department of Dermatology — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Allergic Contact Dermatitis

Explore by condition: All Allergic Contact Dermatitis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗